Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 11 Best Short-Term Stocks to Invest in. The company’s weekly stock ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

We recently published 10 Stocks Crushing With Whopping Double-Digit Gains. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet. Click here to read an analysis of APLS ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) saw its stock soar 12% after the U.S. Food and Drug Administration (FDA) granted approval for EMPAVELI® (pegcetacoplan), the first approved therapy for C3 ...

The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial.

The FDA has approved Empaveli for the treatment of adult and pediatric patients aged 12 years and older with C3G or primary ...

Apellis Pharmaceuticals Inc. investors’ allegations concerning its injectable eye drug, SYFOVRE, were correctly determined a ...

In other recent news, Apellis Pharmaceuticals reported its first-quarter earnings for 2025, revealing an earnings per share (EPS) of -$0.74, which fell short of the forecasted -$0.34.

Get the detailed quarterly/annual income statement for Apellis Pharmaceuticals, Inc. (APLS). Find out the revenue, expenses and profit or loss over the last fiscal year.